The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Helmi L. Lutsep

Department of Neurology

Oregon Health and Science University

3181 SW Sam Jackson Park Road

CR 131

USA

[email]@ohsu.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, CR 131, USA. 2000 - 2011
  • Oregon Health and Science University and Oregon Stroke Center, Portland, Oregon 97239-3098, USA. 2009
  • Oregon Stroke Center, OHSU, Portland 97201, USA. 2001 - 2006
  • Oregon Stroke Center and Associate Professor, Oregon Health & Science University, Department of Neurology, 3181 SW Sam Jackson Park Road, USA. 2006
  • The University of Arizona, Department of Neurology, Tucson 85750, USA. 2002

References

  1. Update on selecting and adjusting antiplatelet therapy for prevention of noncardiogenic, recurrent ischemic stroke. Lutsep, H. Expert. Rev. Cardiovasc. Ther (2011) [Pubmed]
  2. Symptomatic intracranial stenosis: best medical treatment vs. intracranial stenting. Lutsep, H.L. Curr. Opin. Neurol. (2009) [Pubmed]
  3. Recent clinical trials of antiplatelet therapy in secondary stroke prevention: expectations and results for application in primary care settings. Lutsep, H.L. Am. J. Med. (2009) [Pubmed]
  4. Mechanical endovascular recanalization therapies. Lutsep, H.L. Curr. Opin. Neurol. (2008) [Pubmed]
  5. Vertebrobasilar revascularization rates and outcomes in the MERCI and multi-MERCI trials. Lutsep, H.L., Rymer, M.M., Nesbit, G.M. J. Stroke. Cerebrovasc. Dis (2008) [Pubmed]
  6. New developments in secondary stroke prevention: impact of the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) on clinical management. Lutsep, H.L. J. Stroke. Cerebrovasc. Dis (2007) [Pubmed]
  7. Plasma total homocysteine levels in stroke patients screened for the vitamin intervention for stroke prevention clinical trial in the era of folate fortification. Lutsep, H.L., Campbell, S., Chambless, L.E., Howard, V.J., Toole, J.F. Neuroepidemiology (2006) [Pubmed]
  8. MATCH results: implications for the internist. Lutsep, H.L. Am. J. Med. (2006) [Pubmed]
  9. Thrombolytic and newer mechanical device treatment for acute ischemic stroke. Lutsep, H.L. Expert. Rev. Neurother (2006) [Pubmed]
  10. Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke. Lutsep, H.L. Curr. Drug. Targets. CNS. Neurol. Disord (2005) [Pubmed]
  11. The era of the device in ischemic stroke. Lutsep, H.L. Curr. Neurol. Neurosci. Rep (2004) [Pubmed]
  12. Current status of hemorrhagic stroke and acute nonthrombolytic ischemic stroke treatment. Lutsep, H.L. Stroke (2004) [Pubmed]
  13. Repinotan Bayer. Lutsep, H.L. Curr. Opin. Investig. Drugs (2002) [Pubmed]
  14. Does reversal of ischemia on diffusion-weighted imaging reflect higher apparent diffusion coefficient values?. Lutsep, H.L., Nesbit, G.M., Berger, R.M., Coshow, W.R. J. Neuroimaging (2001) [Pubmed]
  15. An update of neuroprotectants in clinical development for acute stroke. Lutsep, H., Clark, W. Curr. Opin. Investig. Drugs (2001) [Pubmed]
  16. Current status of neuroprotective agents in the treatment of acute ischemic stroke. Lutsep, H.L., Clark, W.M. Curr. Neurol. Neurosci. Rep (2001) [Pubmed]
  17. Association of intracranial stenosis with cortical symptoms or signs. Lutsep, H.L., Clark, W.M. Neurology (2000) [Pubmed]
 
WikiGenes - Universities